Alvotech Launches $125M Public Offering and Private Placement to Boost Capital

Key Facts

In a move reflecting the ongoing need for capital in the biotech sector, Alvotech has launched a capital raise initiative. According to reports, the company commenced an underwritten public offering and a concurrent private placement of ordinary shares to raise a total of $125 million. The proceeds are intended for general corporate purposes, though the final execution remains subject to prevailing market conditions.

This capital injection arrives as peers in the biotechnology space navigate a complex funding environment; for context, industry leader Amgen reported a 22% revenue increase in its most recent quarterly filing per search data. Investors are currently weighing the $125 million offering against potential share dilution, a common dynamic in the healthcare sector that often triggers short-term volatility as the market absorbs new equity supply.

At the close on June 12, 2026, ALVO was priced at $4.17, hovering near its daily low of $4.16. Traders should monitor whether the stock holds this support level as the offering progresses. Looking ahead, the broader market sentiment will likely be shaped by the upcoming U.S. CPI inflation data on June 10, which serves as a critical catalyst for high-growth sectors like biotechnology.